Merck EVP Dean Li sells 10,235 company shares

Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported an open-market sale of common stock.

Accepted by SEC EDGAR 02/10/2026 - 04:04 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported an open-market sale of common stock. On February 10, 2026, he sold 10,235 shares of Merck common stock at a weighted average price of $117.5226 per share.

After this transaction, Li beneficially owned 92,035.05 shares of Merck common stock in direct form. The sale was executed through multiple trades within a price range of $117.5200 to $117.5550, with the reported price reflecting the weighted average across those trades.

Insider Trade Summary

Net Seller: 10,235 shares

Net Sell 1 txn

Insider Li Dean Y

Role Executive VP & President, MRL

Sold 10,235 shs ($1.20M)

Share of Position Sold 10.0%

Type	Security	Shares	Price	Value
Sale	Common Stock	10,235	$117.5226	$1.20M

Holdings After Transaction: Common Stock — 92,035.05 shares (Direct)

Holdings Before and After: Common Stock, 102,270.05 to 92,035.05 shares (Direct)

Other Insiders: 8 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5200 to $117.5550, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transaction did Merck (MRK) executive Dean Y. Li report?

Dean Y. Li reported selling 10,235 shares of Merck common stock in an open-market transaction. The sale occurred on February 10, 2026, at a weighted average price of $117.5226 per share, executed through multiple trades within a narrow price range around that level.

At what price did Dean Y. Li sell his Merck (MRK) shares?

The reported sale used a weighted average price of $117.5226 per share. The shares were sold in multiple transactions, with individual trade prices ranging from $117.5200 to $117.5550, and the weighted average figure summarizes those separate executions into a single disclosed number.

How many Merck (MRK) shares does Dean Y. Li own after the reported sale?

Following the reported transaction, Dean Y. Li beneficially owned 92,035.05 shares of Merck common stock. This figure reflects his direct holdings after selling 10,235 shares and represents the amount shown in the Form 4 as beneficially owned following the transaction.

What role does Dean Y. Li hold at Merck (MRK) in this Form 4 filing?

Dean Y. Li is identified as an officer of Merck & Co., Inc., serving as Executive VP & President, MRL. This officer status makes him a reporting person under Section 16, requiring disclosure of his transactions in Merck common stock on Form 4.

Was Dean Y. Li’s Merck (MRK) stock sale a single trade or multiple trades?

The sale was executed through multiple trades rather than a single transaction. The filing notes that the weighted average price of $117.5226 reflects trades completed at prices between $117.5200 and $117.5550, and detailed breakdowns are available upon request to the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Li Dean Y

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NJ 07065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive VP & President, MRL

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		S		10,235	D	$117.5226(1)	92,035.05	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.5200 to $117.5550, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

	/s/ Kelly E. W. Grez as Attorney-in-Fact for Dean Y. Li	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.